Clinical Trials Browser

Unknown × OTHER × Triple Negative Breast Neoplasms × Clear all

NCT04739670 2024-03-01

BELLA

Phase 2 Unknown

Recurrence, Triple Negative Breast Neoplasms

NCT03818685 2024-02-12

BreastImmune03

Phase 2 Unknown

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT05266937 2024-02-01

Atezolizumab Plus CArboplatin Plus Nab-paclitaxel

Phase 2 Unknown

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT04914390 2024-01-22

NeoATCT

Phase 2 Unknown

Triple Negative Breast Neoplasms

NCT04395989 2023-12-22

FUTURE-SUPER

Phase 2 Unknown

Triple Negative Breast Neoplasms

NCT04734262 2023-11-18

SPARK

Phase 2 Unknown

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT05928780 2023-07-03

An Umbrella Trial Based on Molecular Pathway for Patients With Metastatic TNBC in First-line Treatment (FUTURE-Trop2)

Phase 1/2 Unknown

Triple Negative Breast Neoplasms

NCT03920488 2023-06-28

PERSONA

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT05910710 2023-06-20

Impact of Immuno-Oncologic Agent on Neoadjuvant Chemotherapy in Triple Negative Breast Cancer

Triple Negative Breast Neoplasms

NCT05302778 2023-05-25

HERMIONE-10

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT05872412 2023-05-25

Effect of Platinum-based Versus Non-platinum-based Neoadjuvant Chemotherapy in Triple-negative Breast Cancer

Phase 2 Unknown

Triple Negative Breast Neoplasms

NCT05831553 2023-05-06

TIP

Triple Negative Breast Neoplasms

NCT05556200 2023-04-12

A Phase II Trial of Camrelizumab in Combination With Apatinib for Neoadjuvant Treatment of Early-stage TNBC With a High Proportion of TILs

Phase 2 Unknown

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT05746728 2023-04-06

Surufatinib Combined With Tislelizumab in the Second-line and Further Treatment of Triple-negative Breast Cancer

Phase 1/2 Unknown

Triple Negative Breast Neoplasms

NCT04365790 2023-03-08

Investigation of Gene Mutations in Patients With Triple-negative and Patients With HER2+ Breast Cancer Adenocarcinoma

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT03475953 2023-03-03

REGOMUNE

Phase 1/2 Unknown

BreastEndocrineGastrointestinalGenitourinaryHead & NeckNETOther solid neoplasmSarcomaThoracic

Gastro-enteropancreatic neuroendocrine tumor, Turcot syndrome, Tertiary Lymphoid Structures, Mesothelioma, Malignant, Biliary Tract Neoplasms, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Carcinoma, Transitional Cell, Carcinoma, Hepatocellular, Neoplasm Metastasis, Sarcoma, Stomach Neoplasms, Thyroid Neoplasms, Triple Negative Breast Neoplasms

NCT05670925 2023-02-28

A Trial Exploring the Opportune Administration of Nab-paclitaxel in the First Line Treatment, Camrelizumab Combined With Nab-paclitaxel and Famitinib, of TNBC.

Phase 2 Unknown

Triple Negative Breast Neoplasms

NCT05692661 2023-01-20

A Dose Escalation Study of Proton and Carbon Ion Irradiation for HER2 Positive and Triple Negative Breast Cancer

Phase 1 Unknown

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT04248998 2023-01-18

BREAKFAST

Phase 2 Unknown

Triple Negative Breast Neoplasms

NCT05390476 2022-11-04

Tucidinostat and Metronomic Capecitabine for Metastatic Triple-negative Breast Cancer:a Multicenter,Open-label, Randomized Controlled, Phase II Clinical Trial

Phase 2 Unknown

Triple Negative Breast Neoplasms

NCT03907800 2022-10-27

NeoPATH

Phase 2 Unknown

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT03805399 2022-08-10

FUTURE

Phase 1/2 Unknown

Triple Negative Breast Neoplasms

NCT05491694 2022-08-08

HIFU

Phase 2 Unknown

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT04297267 2022-07-22

nonpCR GP

Phase 2 Unknown

Triple Negative Breast Neoplasms

NCT05461690 2022-07-18

Phase II Study of Niraparib in Metastatic TNBC Patients With Homologous Recombination Deficiency

Phase 2 Unknown

Triple Negative Breast Neoplasms

NCT05438706 2022-06-30

A Clinical Study of the Efficacy and Safety of Chidamide in Combination With Camrelizumab and Carboplatin or Capecitabine in the Second and Third Line Treatment of Relapsed/Metastatic Triple-negative Breast Cancer

Phase 2 Unknown

Neoplasm Metastasis, Triple Negative Breast Neoplasms

NCT05303038 2022-06-09

Castle06(BC)

Phase 2 Unknown

Triple Negative Breast Neoplasms

NCT02341911 2022-04-20

TNBC

Phase 2 Unknown

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT03251313 2022-04-20

PD-1(Programmed Death-1) Antibody +GP as First Line Treatment for Triple Negative Breast Cancer(TNBC) Patients

Phase 1 Unknown

Triple Negative Breast Neoplasms

NCT04192903 2022-04-20

Chidamide Combined With Cisplatin for Relapsed or Metastatic Triple-negative Breast Cancer

Phase 2 Unknown

Triple Negative Breast Neoplasms

NCT04609215 2022-04-20

ImmunoBreast - A Phase Ib Study

Phase 1/2 Unknown

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT04745975 2022-04-20

Guided Treatment Based on Mini-PDX in Metastatic Triple Negative Breast Cancer

Phase 2 Unknown

Triple Negative Breast Neoplasms

NCT04457700 2022-04-18

CT-based Radiomics of ALN pCR (ypN0) in Breast Cancer Undergoing NAC

Pathologic Complete Response, Breast Neoplasms, Triple Negative Breast Neoplasms

NCT05288127 2022-03-21

Efficacy of Talazoparib in Asian Metastatic Breast Cancer Patients With a Homologous Recombinant Deficiency (HRD) Signature

Phase 2 Unknown

Triple Negative Breast Neoplasms

NCT03145961 2022-02-24

c-TRAK-TN

Phase 2 Unknown

Triple Negative Breast Neoplasms

NCT04129996 2022-01-11

A Trial of Camrelizumab in Combination With Nab-paclitaxel and Famitinib as a First Line Treatment in Patients With Unresectable Locally Advanced or Metastatic Immunomodulatory Triple Negative Breast Cancer(FUTURE-C-PLUS)

Phase 2 Unknown

Triple Negative Breast Neoplasms

NCT05088057 2021-10-21

Neoadjuvant Camrelizumab Plus Chemotherapy in Triple Negative Breast Cancer

Phase 2 Unknown

Triple Negative Breast Neoplasms

NCT04045522 2021-07-20

Study on Bisphosphonates Targeting Triple-negative Breast Cancer

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT04913571 2021-06-04

TEMPLATE

Phase 2 Unknown

Triple Negative Breast Neoplasms

NCT04907344 2021-05-28

Study of Camrelizumab Plus Chemotherapy as Neoadjuvant Therapy in Participants With Triple Negative Breast Cancer (TNBC)

Phase 2/3 Unknown

Triple Negative Breast Neoplasms

NCT04809779 2021-03-22

NeoPD1TNBC

Phase 2 Unknown

Triple Negative Breast Neoplasms

NCT04755868 2021-02-16

Talazoparib Maintenance Therapy in Triple-negative Breast Cancer

Phase 2 Unknown

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT04676997 2020-12-21

Neoadjuvant Study of Camrelizumab Plus Chemotherapy in Triple Negative Breast Cancer (TNBC)

Phase 2 Unknown

Triple Negative Breast Neoplasms

NCT04669522 2020-12-17

PSY-ONC TNBC

Triple Negative Breast Neoplasms

NCT04582955 2020-12-07

Neoadjuvant Treatment of Early Triple-negative Breast Cancer With Chidamide and Chemotherapy

Phase NA Unknown

Triple Negative Breast Neoplasms

NCT03617341 2020-10-27

Brain Monitoring for High Risk of Brain Metastases in Metastatic Breast Cancer

Brain Neoplasms, Breast Neoplasms, Triple Negative Breast Neoplasms

NCT04517292 2020-08-18

GEP

Phase 2 Unknown

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT04502680 2020-08-11

EMBRAVE-001

Phase 2 Unknown

Triple Negative Breast Neoplasms

NCT03044730 2020-07-13

Pembrolizumab and Capecitabine in Treating Patients With Locally Advanced or Metastatic Triple Negative or Hormone-Refractory Breast Cancer That Cannot Be Removed by Surgery

Phase 2 Unknown

30 enrolled 11 charts

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT04403529 2020-06-01

Evaluating the Clinical Value of Traditional Chinese Medicine in the Adjuvant Therapy of Triple-negative Breast Cancer

Phase 3 Unknown

Triple Negative Breast Neoplasms